Russia's ChemRar gets rights to Pfizer's DPP-IVi diabetes candidate

Russia’s ChemRar Hi-Tech Centre, a pharmaceutical investment and R&D group, said yesterday that global drugs behemoth Pfizer (NYSE: PFE) has granted exclusive development and marketing rights to SatRx for its DPP(1)-IVi compound, PF-00734200.

SatRX, a ChemRar group company, is developing PF-00734200 for type 2 diabetes, one of the most burdensome chronic non-communicable diseases, which is fast reaching epidemic proportions throughout the world.

Under the terms of the license, signed during the St Petersburg Economic Forum last month, Pfizer granted exclusive worldwide rights (ex-China) development and commercialization of PF-00734200 as monotherapy or in combination with certain other therapies. Pfizer will receive undisclosed royalties and milestone payments based on commercialization activities. The agreement was developed as partial fulfillment of a Memorandum of Understanding reached last year (The Pharma Letter July 1, 2011), under which Pfizer and ChemRar agreed to explore collaborations focused on research, development and commercialization of innovative compounds and vaccines to treat cardiometabolic, infectious and oncologic diseases in Russia and other countries.